Humanigen, Inc.
https://www.humanigen.com/
Already a Biomedtracker subscriber?
You have access to the full company record through your subscription
Want to become a subscriber?
Subscribers get more company details, updates, company financials and company products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Humanigen, Inc.
Humanigen Isn’t Throwing In The Towel On Lenzilumab For COVID-19 Just Yet
The company is assessing a potential path forward in COVID-19 for the drug and is in talks with platform study groups after a Phase III study did not show statistical significance, but still showed activity.
Publisher’s Spotlight: Citeline Awards Honor R&D Excellence
Pharma Intelligence congratulates the winners of the 2021 Citeline Awards.
Publisher’s Spotlight: Citeline Awards Honor R&D Excellence
Pharma Intelligence congratulates the winners of the 2021 Citeline Awards.
Finance Watch: A Dozen Deals Add Up To $672m In Biopharma Venture Capital
Ventus Therapeutics raised a $140m series C while Endeavor Biomedicines brought in $101m in series B cash. Also, Twist Bioscience grossed $250m in a follow-on offering, BioMarin raised $110m when it sold a priority review voucher and Nuvectis, TC BioPharm launched IPOs.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
- Other Names / Subsidiaries
-
- KaloBios Pharmaceuticals, Inc.
- Humanigen Australia Pty Ltd